News

Phase 1 trial of SION-109 oral therapy doses first volunteer

The first volunteer has been dosed in a Phase 1 clinical trial evaluating SION-109, an experimental oral treatment for cystic fibrosis (CF), as announced by Sionna Therapeutics, the therapy’s developer. After receiving the green light from the U.S. Food and Drug Administration, the trial has enrolled healthy volunteers to…

Stopping dornase alfa while on Trikafta may save $1B

Discontinuing dornase alfa while on Trikafta (elexacaftor/tezacaftor/ivacaftor) could cut down on prescription costs by more than $1 billion each year in the U.S., according to estimates based on data from a randomized controlled trial. The savings would not compromise health, at least not for the short term, as people…

2 imaging techniques can detect liver issues in CF children: Study

Two imaging techniques, called elastography and spectroscopy, can detect liver stiffness (hardness) and the buildup of fat in the liver in children with cystic fibrosis (CF) — particularly among those with CF-related liver disease — a study found. Importantly, because elastography and spectroscopy are noninvasive, these scans may offer…

Vanderbilt’s pediatric center earns CF Foundation honor

The Cystic Fibrosis Foundation has honored the Pediatric Cystic Fibrosis Diagnosis and Treatment Center at Monroe Carell Jr. Children’s Hospital at Vanderbilt University with its 2023 Outstanding Care Center Partnership Award. The annual award is in recognition of the collaborations and commitment of the Nashville, Tennessee, center to…

Registration is open for BreatheCon 2024, Feb. 9-10

The eighth annual BreatheCon, a virtual event hosted by the Cystic Fibrosis Foundation that brings together adults with cystic fibrosis (CF), is coming up Feb. 9-10. BreatheCon 2024 will focus on the individual experience of the CF journey. Participants will have opportunities to share their own stories,…